The emergence of HIV resistance and new antiretrovirals: are we winning?
Section snippets
HIV drug resistance
This topic was discussed at the 11th CROI in two different oral sessions. In addition, excellent posters were presented on this subject on this same day. Highlights are as follows.
New antiretroviral agents
The conference also featured important papers on new and investigational drugs. These compounds are being developed either because they are directed against novel targets or because they have resistance profiles that may inhibit the replication of viruses containing drug resistance mutations in the viral reverse transcriptase and/or protease genes.
Conclusions
Resistance to every HIV drug class is clearly emerging and, alarmingly, transmission sometimes involves resistant strains that can cripple the effectiveness of combination chemotherapy. However, new agents, not cross-resistant with existing drugs, are being developed on a regular basis. This affords hope to patients who harbor viruses resistant to a variety of currently approved products. Whether the discovery of new agents keep resistance at bay in the future is of obvious concern given the
References (34)
- et al.
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy
Antivir. Ther.
(2002) - Bethell, R., Adams, J., De Muys, J., et al., 2004. Pharmacological evaluation of a dual deoxycytidine analogue...
- Bonneau, P.R., Doyon, L., Duan, J., et al., 2004. Characterization of a novel series of nevirapine-like next-generation...
- Cahn, P., Lange, J., Cassetti, I., et al., 2003. Anti HIV-1 activity of SPD754, a new NRTI: results of a 10-day...
- Charpentier, C., Morand-Joubert, L., Chene, G., Girard, P.-M., Clavel, F., Hance, A.J., 2004. Detection of pre-existing...
- Collins, P., Shiveley, L., Anderson, C., Bethell, R., 2004. Analysis of the genotypes of viruses isolated from patients...
- Demarest, J., Adkison, K., Sparks, S., et al., 2004. Single and multiple dose escalation study to investigate the...
- De Meyer, S., Van Marck, H., Van Den Bulcke, T., et al., 2004. Phenotypic and genotypic profiling of TMC114, a potent...
- Elion, R., Cohen, C., DeJesus, E., et al., 2004. COL40263: resistance and efficacy of once-daily Trizivir and tenofovir...
- Franti, M., Ramos, L., Maloveste, S., et al., 2004. Control of HIV-1 replication in the hu-PBL-SCID mouse model by an...
Cited by (11)
A novel method for distinguishing between dsDNA and ssRNA virus infections
2008, Journal of Clinical VirologyCitation Excerpt :Correspondingly, at a prevalence of 0–70%, a DNAVS point of less than 1.5 (negative test result) practically rules out dsDNA virus infection. Reliably tested specific antiviral agents are available only for a few viral agents, e.g. nucleoside analogues for herpesviruses (Hewlett et al., 2004), neuraminidase inhibitors for influenza viruses (Jefferson et al., 2006), and antiretrovirals for HIV (Wainberg, 2004). To commence proper antiviral treatment as rapidly as possible, timely knowledge of whether the infection is caused by dsDNA or ssRNA virus would be beneficial for the clinician.
Resistance to tyrosine kinase inhibitors: Calling on extra forces
2005, Drug Resistance UpdatesHIV/AIDS, a Long Wave Event: Sundering the Intergenerational Bond
2016, AIDS and GovernancePhagocytic cell surface markers in medical microbiological research and diagnosis
2012, The Role of New Technologies in Medical Microbiological Research and DiagnosisA long wave event: HIV/AIDS, politics, governance and 'security': Sundering the intergenerational bond?
2008, The Politics of AIDS: Globalization, the State and Civil SocietyThe role of zidovudine on erradication of vertical transmission of AIDS
2008, Latin American Journal of Pharmacy